(NASDAQ: EQ) Equillium's forecast annual revenue growth rate of -23.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Equillium's revenue in 2025 is $16,553,000.On average, 1 Wall Street analysts forecast EQ's revenue for 2027 to be $982,993,244, with the lowest EQ revenue forecast at $982,993,244, and the highest EQ revenue forecast at $982,993,244. On average, 1 Wall Street analysts forecast EQ's revenue for 2028 to be $3,075,721,597, with the lowest EQ revenue forecast at $3,075,721,597, and the highest EQ revenue forecast at $3,075,721,597.
In 2029, EQ is forecast to generate $5,310,067,621 in revenue, with the lowest revenue forecast at $5,310,067,621 and the highest revenue forecast at $5,310,067,621.